

Paper Title

Author's Full Name^{1,*}, Author's Full Name^{1,2}

¹Department/Faculty, University, City, Country

²Department, Institute/Organization, City, Country

Email address:

email1@authorname.com (author name1), email2@authorname.com (author name2)

*Corresponding author

To cite this article:

Author's Name. Paper Title. *International Journal of Research in Vocational Studies (IJRVOCAS)*, X(X), XX–XX.
<https://doi.org/10.53893/ijrvocas.v1iX.XX>.

Received: MM DD, 2025; **Revised:** MM DD, 2025; **Accepted:** MM DD, 2025; **Published:** MM DD, 2025



IJRVOCAS is licensed under a [Creative Commons Attribution 4.0 International License](https://creativecommons.org/licenses/by/4.0/).

Abstract: An abstract is a short summary of your research paper, usually about a paragraph (200-400 words) long. A well-written abstract can let readers get the essence of your paper, prepare readers to follow the detailed information, analyses, and arguments in your full paper, and help readers remember the key points.

Keywords: Keyword1, Keyword2 ... Keyword8

1. Introduction

This template, created in MS Word 2000/2007/2010 and saved as “Word 97-2000 & 6.0/95 – RTF” for the PC, provides authors with most of the formatting specifications needed for preparing electronic versions of their papers. All standard paper components have been specified for three reasons: (1) ease of use when formatting individual papers, (2) automatic compliance to electronic requirements that facilitate the concurrent or later production of electronic products, and (3) conformity of style throughout a journal publication. Margins, column widths, line spacing, and type styles are built-in; examples of the type styles are provided throughout this document. Some components, such as multi-leveled equations, graphics, and tables are not prescribed, although the various table text styles are provided. The formatter will need to create these components, incorporating the applicable criteria that follow.

2. Custom Title (IJRVOCAS-Level1-Multiple-line)

2.1. IJRVOCAS-Level2

First, confirm that you have the correct template for your paper size. This template has been tailored for output on the A4 paper size.

2.2. IJRVOCAS-Level2

The template is used to format your paper and style the text. All margins, column widths, line spaces, and text fonts are prescribed; please do not alter them. You may note peculiarities. For example, the head margin in this template measures proportionately more than is customary. This measurement and others are deliberate, using specifications that anticipate your paper as one part of the entire publication, and not as an independent document. Please do not revise any of the current designations.

2.2.1. IJRVOCAS-Level3

Before you begin to format your paper, first write and save the content as a separate text file. Keep your text and graphic files separate until after the text has been formatted and

styled. Do not use hard tabs, and limit use of hard returns to only one return at the end of a paragraph. Do not add any kind of pagination anywhere in the paper. Do not number text heads-the template will do that for you.

2.2.2. Abbreviations (IJRVOCAS-Level3)

Define abbreviations and acronyms the first time they are used in the text, even after they have been defined in the abstract. Abbreviations such as IEEE, SI, MKS, CGS, sc, dc, and rms do not have to be defined. Do not use abbreviations in the title or heads unless they are unavoidable.

2.2.3. Equations (IJRVOCAS-Level3)

The equations are an exception to the prescribed specifications of this template. You will need to determine whether or not your equation should be typed using either the Times New Roman or the Symbol font (please no other font). To create multileveled equations, it may be necessary to treat the equation as a graphic and insert it into the text after your paper is styled.

Equation numbers, within parentheses, are to position flush right, as in (1), using a right tab stop. To make your equations more compact, you may use the solidus (/), the exp function, or appropriate exponents. Italicize Roman symbols for quantities and variables, but not Greek symbols. Use a long dash rather than a hyphen for a minus sign. Punctuate equations with commas or periods when they are part of a sentence, as in

$$X+Y=Z \quad (1)$$

$$X_1-Y^2=R^* \quad (2)$$

Note that the equation is centered using a center tab stop. Be sure that the symbols in your equation have been defined before or immediately following the equation. Use “(1)”, not “Eq. (1)” or “equation (1)”, except at the beginning of a sentence: “Equation (1) is . . .”

3. IJRVOCAS-Level1

3.1. Figure (IJRVOCAS-Level2)

Figure is as follows: Place figures and tables at the top and bottom of columns. Avoid placing them in the middle of columns. Large figures and tables may span across both columns. Figure captions should be below the figures; table heads should appear above the tables. Insert figures and tables after they are cited in the text. Use the “Figure 1”, even at the beginning of a sentence.




Figure 1. The caption of the figure.

If the square-shaped pixel size in our images was 8×8 screen-pixels, this amounted to about 21 pixels per face quantization (an equivalent of about 10.5 cycles/face). With this level of image detail, all three basic varieties of configural information (hange of spatial quantization between 11 pixels/face and 6 pixels/face levels altogether indicate that this ERP- component is especially sensitive to the first-order configural cues. Some other works have supported both of these ideas.



**International Journal of
Research in Vocational
Studies (IJRVOCAS)**

(a) (b) (c)

Figure 2. The figures illustrated here.

3.2. Table (IJRVOCAS-Level2)

Table is as follows: Use words rather than symbols or abbreviations when writing Figure axis labels to avoid confusing the reader. As an example, write the quantity “Magnetization”, or “Magnetization, M”, not just “M”.

Table 1. Table information

Column1	Column2
Row1*	Row1
Row2	Row2
Row3	Row3
Row4	Row4
Row5	Row5
Row6	Row6
Row7	Row7

* The example for this table.

3.3. In-text citations (IJRVOCAS-Level2)

The template will number citations consecutively within brackets [1]. The sentence punctuation follows the bracket [2]. Refer simply to the reference number, as in [3]—do not use “Ref. [3]” or “reference [3]” except at the beginning of a sentence: “Reference [3] was the first . . .”

Number footnotes separately in superscripts. Place the actual footnote at the bottom of the column in which it was cited. Do not put footnotes in the reference list. Use letters for table footnotes.

Unless there are six authors or more give all authors' names; do not use "et al.". Papers that have not been published, even if they have been submitted for publication, should be cited as "unpublished" [4-8]. Papers that have been accepted for publication should be cited as "in press" [9-12]. Capitalize only the first word in a paper title, except for proper nouns and element symbols.

For papers published in translation journals, please give the English citation first, followed by the original foreign-language citation [13-15].

4. Conclusion

After the text edit has been completed, the paper is ready for the template. Duplicate the template file by using the Save As command, and use the naming convention prescribed by your conference for the name of your paper. In this newly created file, highlight all of the contents and import your prepared text file. You are now ready to style your paper; use the scroll down window on the left of the MS Word Formatting toolbar.

Acknowledgements

You as the author are free to decide whether to include acknowledgments or not. Usually, the acknowledgments section includes the names of people who in some way contributed to the work, but do not fit the criteria to be listed as the authors. This section of your manuscript can also include information about funding sources.

References

- [1] Alimehmeti, I. (2021). Efficacy and Safety of AZD1222, BNT162b2 and mRNA-1273 vaccines against SARS-CoV-2. *Albanian Journal Of Trauma And Emergency Surgery*, 5(1), 791-796. doi: 10.32391/ajtes.v5i1.178
- [2] Bos, F., & Ruijs, A. (2021). Quantifying the Non-Use Value of Biodiversity in Cost-Benefit Analysis: The Dutch Biodiversity Points. *Journal Of Benefit-Cost Analysis*, 12(2), 287-312. doi: 10.1017/bca.2020.27
- [3] Bryant, A., Lawrie, T., & Fordham, E. (2021). Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines. *American Journal of Therapeutics*, 28, e434–e460, July 2021. *American Journal Of Therapeutics*, 28(5), e573–e576. doi: 10.1097/mjt.0000000000001442
- [4] CZucman, N., Uhel, F., Descamps, D., Roux, D., & Ricard, J. (2021). Severe Reinfection With South African Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variant 501Y.V2. *Clinical Infectious Diseases*. doi: 10.1093/cid/ciab129
- [5] Drupp, M., & Hänsel, M. (2021). Relative Prices and Climate Policy: How the Scarcity of Nonmarket Goods Drives Policy Evaluation. *American Economic Journal: Economic Policy*, 13(1), 168-201. doi: 10.1257/pol.20180760
- [6] Hariyanto, T., Halim, D., Rosalind, J., Gunawan, C., & Kurniawan, A. (2021). Ivermectin and outcomes from Covid-19 pneumonia: A systematic review and meta-analysis of randomized clinical trial studies. *Reviews In Medical Virology*. doi: 10.1002/rmv.2265
- [7] Hill, A., Garratt, A., Levi, J., Falconer, J., Ellis, L., & McCann, K. et al. (2021). Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection. *Open Forum Infectious Diseases*. doi: 10.1093/ofid/ofab358
- [8] Klompas, M. (2021). Understanding Breakthrough Infections Following mRNA SARS-CoV-2 Vaccination. *JAMA*. doi: 10.1001/jama.2021.19063
- [9] Kory, P., Meduri, G., Varon, J., Iglesias, J., & Marik, P. (2021). Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19. *American Journal Of Therapeutics*, 28(3), e299–e318. doi: 10.1097/mjt.0000000000001377
- [10] Kow, C., Merchant, H., Mustafa, Z., & Hasan, S. (2021). The association between the use of ivermectin and mortality in patients with COVID-19: a meta-analysis. *Pharmacological Reports*, 73(5), 1473-1479. doi: 10.1007/s43440-021-00245-z
- [11] Marciniak, S., Farrell, J., Rostron, A., Smith, I., Openshaw, P., & Baillie, J. et al. (2021). COVID-19 pneumothorax in the UK: a prospective observational study using the ISARIC WHO clinical characterisation protocol. *European Respiratory Journal*, 58(3), 2100929. doi: 10.1183/13993003.00929-2021
- [12] Mukarram, M. (2021). Ivermectin Use Associated with Reduced Duration of Covid-19 Febrile Illness in a Community Setting. *International Journal Of Clinical Studies And Medical Case Reports*, 13(4). doi: 10.46998/ijcmcr.2021.13.000320
- [13] Okumuş, N., Demirtürk, N., Çetinkaya, R., Güner, R., Avcı, İ., & Orhan, S. et al. (2021). Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients. *BMC Infectious Diseases*, 21(1). doi: 10.1186/s12879-021-06104-9
- [14] Yeh, H. (2021). The Potential Declining Efficacy of the ChAdOx1 nCoV-19 Vaccine (AZD1222) on Inoculators With Nonsteroidal Anti-inflammatory Drug (NSAID) Intake. *Clinical Infectious Diseases*. doi: 10.1093/cid/ciab516
- [15] Zaidi, A., & Dehgani-Mobaraki, P. (2021). RETRACTED ARTICLE: The mechanisms of action of Ivermectin against SARS-CoV-2: An evidence-based clinical review article. *The Journal Of Antibiotics*. doi: 10.1038/s41429-021-00430-5